Yanni J M, Weimer L K, Glaser R L, Lang L S, Robertson S M, Spellman J M
Allergy/Inflammation Research, Alcon Laboratories Inc., Fort Worth, Tex 76134-2099.
Int Arch Allergy Immunol. 1993;101(1):102-6. doi: 10.1159/000236505.
The antiallergic compound, lodoxamide, was evaluated for its abilities to attenuate a local allergic reaction in rat conjunctiva in vivo and to inhibit rat conjunctival mast cell mediator release in vitro. Topically applied lodoxamide (0.01, 0.10 and 1.0%, w/v) dose-dependently reduced the allergic response (23, 43 and 72%, respectively) in vivo. Lodoxamide was more effective than cromolyn sodium, N-acetyl aspartyl glutamic acid (Naaxia) and levocabastine, and 25 (7-200) times more potent than nedocromil sodium in direct comparisons. Addition of lodoxamide (10 micrograms/ml) to sensitized conjunctival tissue in vitro immediately prior to antigen challenge significantly reduced the amount of histamine released by the tissue. These data suggest that lodoxamide's in vivo anti-allergic activity in the conjunctiva is associated with its ability to prevent allergic mediator release from mast cells contained in this same tissue.
对抗过敏化合物洛度沙胺进行了评估，考察其在体内减轻大鼠结膜局部过敏反应以及在体外抑制大鼠结膜肥大细胞介质释放的能力。局部应用洛度沙胺（0.01%、0.10%和1.0%，w/v）在体内呈剂量依赖性地减轻过敏反应（分别为23%、43%和72%）。在直接比较中，洛度沙胺比色甘酸钠、N - 乙酰天冬氨酰谷氨酸（Naaxia）和左卡巴斯汀更有效，且效力比奈多罗米钠强25（7 - 200）倍。在抗原攻击前立即向体外致敏的结膜组织中添加洛度沙胺（10微克/毫升）可显著减少该组织释放的组胺量。这些数据表明，洛度沙胺在结膜中的体内抗过敏活性与其阻止同一组织中肥大细胞释放过敏介质的能力有关。
